Scientists resume COVID-19 trials of hydroxychloroquine

Study on use of hydroxychloroquine for COVID-19 pulled

Study on use of hydroxychloroquine for COVID-19 pulled

"This is a really important result, at last providing unequivocal evidence that hydroxychloroquine is of no value in treatment of patients hospitalised with COVID-19", said Peter Openshaw, a professor at Imperial College London, in reaction to the results.

Despite the retraction, hydroxychloroquine should still be approached with caution as other studies are still sticking to their conclusions that the drug has little to no effect on Covid-19.

A study that suggested antimalarial drugs such as hydroxychloroquine were unsafe for those with COVID-19 has been retracted.

Lancet previously admitted "concern" over the study, after troubling facts about Surgisphere came to light, but did not officially retract it until now.

In its retraction notice regarding the article, The Lancet today said it could no longer vouch for the veracity of primary data used in the research.

Scientists acknowledge, though, that studies are being conducted at break-neck speed while garnering unprecedented levels of attention that could give findings unwarranted weight.

Regardless of this massive study of hydroxychloroquine, which should now be ruled out, other research on the drug indicates that the antimalarial is not effective against COVID-19 and can not prevent infection.

"We launched an independent third party peer review of Surgisphere with the consent of Sapan Desai to evaluate the origination of the database elements, to confirm the completeness of the database, and to replicate the analyses presented in the paper", they added.

McHenry County reports 4 additional deaths, 20 new coronavirus cases
An Associated Press story on June 1 noted that reports of nursing home deaths are partial at this stage, and likely to go higher. Federal officials acknowledged there may be inaccuracies because nursing homes just started reporting the data last month.

After a request from the UK Medicines and Healthcare Products Regulatory Agency the trial investigators reviewed the data on the hydroxychloroquine arm of the study. Surgisphere was said to have provided the data from 671 hospitals on six continents.

But the World Health Organization (WHO) on 25 May said that they will not conduct tests using Hydroxychloroquine anymore after a study raised side effects of the drug.

Despite being promoted by US President Donald Trump as a "game-changer", the anti-malaria drug hydroxychloroquine, unfortunately, can not cure patients with coronavirus.

The results come from a study called RECOVERY, funded by the United Kingdom government, that sought to randomly assign large numbers of patients to multiple potential treatments in the country's National Health Service. We deeply apologize to you, the editors and readers of the magazine for any embarrassment or inconvenience this may have caused.

It was released on the same day as two other studies investigating the same topic, with all three finding that these medicines do not heighten susceptibility to infection, nor increase the risk of becoming seriously ill.

The study co-authors have retracted it, announcing that an independent review of the data was not possible. Many scientists were angry that they had been stopped on the basis of a trial that was observational and not a "gold standard" RCT.

Aside from the New England Journal of Medicine and The Lancet, the research was also widely published by major media organisations across the world, with a lot of them citing both organisation's long-standing credibility in the publication of scientific breakthroughs.

Recommended News

We are pleased to provide this opportunity to share information, experiences and observations about what's in the news.
Some of the comments may be reprinted elsewhere in the site or in the newspaper.
Thank you for taking the time to offer your thoughts.